Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). (Q33224640)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

0 references

Victor A. Gault

object named as

Victor A Gault

2

0 references

object named as

Nigel Irwin

1

0 references

object named as

Peter R Flatt

7

0 references

Clifford J Bailey

object named as

Clifford J Bailey

6

1 reference

ORCID Public Data File 2021

Patrick Harriott

5

object named as

Patrick Harriott

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

author name string

Brian D Green

3

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Brett Greer

4

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Finbarr P M O'Harte

8

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

publication date

1 July 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Biological Chemistry

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

386

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

679-687

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

The entero-insular axis in type 2 diabetes--incretins as therapeutic agents

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP).

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Structure-function analysis of a series of novel GIP analogues containing different helical length linkers

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Gastric inhibitory polypeptide: the neglected incretin revisited

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Gastric inhibitory polypeptide does not inhibit gastric emptying in humans

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

GIP biology and fat metabolism

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion

1 reference

https://api.crossref.org/works/10.1515%2FBC.2005.079

21 January 2018

Identifiers

10.1515/BC.2005.079

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33224640&oldid=1859105245"